HealthDay News — Cytoskeleton-associated protein 4 (CKAP4) appears to be a novel serodiagnostic marker for lung cancer, with increased levels in lung cancer patients versus healthy controls, according to a study published online May 8 in The American Journal of Pathology.
Kengo Yanagita, from Kitasato University in Tokyo, and colleagues examined the utility of KU-Lu-1 antibody, recognizing CKAP4, as a serodiagnostic marker for lung cancer. Using sera of 271 lung cancer patients and 100 healthy controls, reverse-phase protein array analysis was performed.
The researchers detected CKAP4 in lung cancer cells and tissues, and confirmed its secretion into the culture supernatant.
Serum CKAP4 levels were significantly higher in lung cancer patients than healthy controls (P < 0.0001); the area under the curve of the receiver operating characteristic curve analysis was 0.890, with 81.1 and 86.0 percent sensitivity and specificity, respectively. Compared with healthy controls, patients with stage I adenocarcinoma or squamous cell carcinoma had serum CKAP4 levels that were significantly higher (P < 0.0001). In the validation set, serum CKAP4 levels were also significantly higher in lung cancer patients than in healthy controls.
“Serum CKAP4 levels may differentiate lung cancer patients from healthy controls, and they may be detected early even in stage I non-small-cell lung cancer,” the authors write. “The present results provide evidence that CKAP4 may be a novel early serodiagnostic marker for lung cancer.”